Antibodies against a particular region of EBNA1 highly cross-react with GlialCAM in MS patients, potentially resulting in “off-target” autoimmune attack against the myelin sheath in CNS of patients with MS (155). Here, HEPACAM is linked to myeloid sarcoma.